HUP0100813A3 - Enhancing the circulating half-life of antibody-based fusion proteins - Google Patents

Enhancing the circulating half-life of antibody-based fusion proteins

Info

Publication number
HUP0100813A3
HUP0100813A3 HU0100813A HUP0100813A HUP0100813A3 HU P0100813 A3 HUP0100813 A3 HU P0100813A3 HU 0100813 A HU0100813 A HU 0100813A HU P0100813 A HUP0100813 A HU P0100813A HU P0100813 A3 HUP0100813 A3 HU P0100813A3
Authority
HU
Hungary
Prior art keywords
antibody
enhancing
life
fusion proteins
circulating half
Prior art date
Application number
HU0100813A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Lexigen Pharmaceuticals Corp L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lexigen Pharmaceuticals Corp L filed Critical Lexigen Pharmaceuticals Corp L
Publication of HUP0100813A2 publication Critical patent/HUP0100813A2/hu
Publication of HUP0100813A3 publication Critical patent/HUP0100813A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HU0100813A 1998-02-25 1999-02-24 Enhancing the circulating half-life of antibody-based fusion proteins HUP0100813A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7588798P 1998-02-25 1998-02-25
PCT/US1999/003966 WO1999043713A1 (en) 1998-02-25 1999-02-24 Enhancing the circulating half-life of antibody-based fusion proteins

Publications (2)

Publication Number Publication Date
HUP0100813A2 HUP0100813A2 (hu) 2001-06-28
HUP0100813A3 true HUP0100813A3 (en) 2003-08-28

Family

ID=22128576

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100813A HUP0100813A3 (en) 1998-02-25 1999-02-24 Enhancing the circulating half-life of antibody-based fusion proteins

Country Status (11)

Country Link
EP (1) EP1060194A1 (cs)
JP (1) JP2002505086A (cs)
CN (1) CN1204147C (cs)
AU (1) AU758240B2 (cs)
BR (1) BR9908226A (cs)
CA (1) CA2320403A1 (cs)
CZ (1) CZ20003099A3 (cs)
HU (1) HUP0100813A3 (cs)
NO (1) NO20004218L (cs)
PL (1) PL199659B1 (cs)
WO (1) WO1999043713A1 (cs)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030109680A1 (en) 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
US7749498B2 (en) 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
PT1037927E (pt) 1997-12-08 2004-10-29 Emd Lexigen Res Ct Corp Proteinas de fusao heterodimericas uteis para imunoterapia de abordagem selectiva e estimulacao imunologica geral
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6242195B1 (en) 1998-04-02 2001-06-05 Genentech, Inc. Methods for determining binding of an analyte to a receptor
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
KR20060067983A (ko) 1999-01-15 2006-06-20 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US7067110B1 (en) 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
AU778611B2 (en) 1999-08-09 2004-12-16 Merck Patent Gmbh Multiple cytokine-antibody complexes
GB9926084D0 (en) * 1999-11-03 2000-01-12 King S College London Recombinant fusion molecules
JP2003514552A (ja) 1999-11-12 2003-04-22 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング 改善された性質を有するエリトロポエチンの形態
ES2269366T3 (es) * 2000-02-11 2007-04-01 Merck Patent Gmbh Mejoramiento de la vida media en circulacion de proteinas de fusion basadas en anticuerpos.
IL151348A0 (en) 2000-04-13 2003-04-10 Univ Rockefeller Enhancement of antibody-mediated immune responses
PT1294401E (pt) 2000-06-29 2007-11-09 Merck Patent Gmbh Aumento das respostas imunológicas mediadas por proteínas de fusão anticorpo-citoquina por tratamento combinado com agentes que aumentam a captação de imunocitoquinas
DE10045591A1 (de) * 2000-09-15 2002-04-04 Klaus Pfizenmaier Ortsspezifische, antikörpervermittelte Aktivierung proapoptotischer Zytokine - AMAIZe (Antibody-Mediated Apoptosis Inducing Zytokine)
AU2011253690C1 (en) * 2000-12-12 2018-01-18 Board Of Regents, The University Of Texas System Molecules with extended half-lives, compositions and uses thereof
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
CA2431600C (en) 2000-12-12 2012-04-17 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
HUP0303428A2 (hu) 2001-03-07 2004-01-28 Merck Patent Gmbh. Expressziós eljárás hibrid izotípusú antitestcsoportot tartalmazó fehérjékhez
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
PL205352B1 (pl) 2001-05-03 2010-04-30 Merck Patent Gmbh Rekombinowane przeciwciało specyficzne dla nowotworu
TWI338009B (en) * 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
KR100988180B1 (ko) 2001-12-04 2010-10-18 메르크 파텐트 게엠베하 조절된 선택성을 갖는 면역시토카인
DK1495055T3 (da) * 2002-04-18 2013-11-11 Genencor Int Produktion af funktionelle antistoffer i filamentøse svampe
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US8968730B2 (en) 2002-08-14 2015-03-03 Macrogenics Inc. FcγRIIB specific antibodies and methods of use thereof
US8946387B2 (en) 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
WO2004035752A2 (en) * 2002-10-15 2004-04-29 Protein Design Labs, Inc. ALTERATION OF FcRn BINDING AFFINITIES OR SERUM HALF-LIVES OF ANTIBODIES BY MUTAGENESIS
US7217797B2 (en) * 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US7217798B2 (en) 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
CN100432105C (zh) 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
AU2004239244C1 (en) 2003-05-06 2015-04-23 Bioverativ Therapeutics Inc. Clotting factor-Fc chimeric proteins to treat hemophilia
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
JP2005073528A (ja) * 2003-08-28 2005-03-24 Genetics Inst Llc 生物学的系における生物学的組織への血球の接着を阻害する方法、ならびにその方法に使用するための組成物
CN100467488C (zh) 2003-12-30 2009-03-11 默克专利有限公司 Il-7融合蛋白
CN1902222A (zh) 2003-12-31 2007-01-24 默克专利有限公司 具有改善药物代谢动力学的Fc－促红细胞生成素融合蛋白质
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
DE602005020837D1 (de) 2004-12-09 2010-06-02 Merck Patent Gmbh Il-7-varianten mit reduzierter immunogenität
US9889197B2 (en) 2005-04-15 2018-02-13 Macrogenics, Inc. Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin
US11254748B2 (en) 2005-04-15 2022-02-22 Macrogenics, Inc. Covalent diabodies and uses thereof
ES2707152T3 (es) 2005-04-15 2019-04-02 Macrogenics Inc Diacuerpos covalentes y usos de los mismos
US9963510B2 (en) 2005-04-15 2018-05-08 Macrogenics, Inc. Covalent diabodies and uses thereof
US9284375B2 (en) 2005-04-15 2016-03-15 Macrogenics, Inc. Covalent diabodies and uses thereof
SI2298815T1 (sl) 2005-07-25 2015-08-31 Emergent Product Development Seattle, Llc Zmanjšanje števila celic b z uporabo molekul, ki se specifično vežejo na cd37 in cd20
LT2573114T (lt) 2005-08-10 2016-10-10 Macrogenics, Inc. Atpažinimas ir konstravimas antikūnų su variantinėmis fc sritimis ir jų panaudojimo būdai
MX2008015524A (es) 2006-06-12 2009-01-13 Trubion Pharmaceuticals Inc Proteinas de union multivalentes monocatenarias con funcion efectora.
EP2032159B1 (en) 2006-06-26 2015-01-07 MacroGenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
HUE030269T2 (en) 2006-06-26 2017-04-28 Macrogenics Inc FC RIIB-specific antibodies and methods for their use
ES2352561T3 (es) * 2006-06-30 2011-02-21 Conaris Research Institute Ag Dímeros de sgp 130fc mejorados.
US8652466B2 (en) 2006-12-08 2014-02-18 Macrogenics, Inc. Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting
TW200907056A (en) * 2007-03-28 2009-02-16 Astrazeneca Ab New method
PE20140196A1 (es) 2007-08-09 2014-03-19 Boehringer Ingelheim Int Anticuerpos anti-cd37
EP2219672B1 (en) 2007-11-09 2016-02-17 Peregrine Pharmaceuticals, Inc. Anti-vegf antibody compositions and methods
WO2009117030A2 (en) 2007-12-19 2009-09-24 Macrogenics, Inc. Improved compositions for the prevention and treatment of smallpox
JP2011509675A (ja) 2008-01-18 2011-03-31 メディミューン，エルエルシー 部位特異的コンジュゲーションのためのシステイン操作抗体
WO2009123894A2 (en) 2008-04-02 2009-10-08 Macrogenics, Inc. Her2/neu-specific antibodies and methods of using same
MX2010010387A (es) 2008-04-02 2010-10-15 Macrogenics Inc Anticuerpos especificos para el complejo de bcr y metodos para el uso de los mismos.
CN102099377A (zh) 2008-04-11 2011-06-15 新兴产品开发西雅图有限公司 Cd37免疫治疗剂及其与双功能化学治疗剂的联合
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
EP2373689A1 (en) 2008-12-12 2011-10-12 MedImmune, LLC Crystals and structure of a human igg fc variant with enhanced fcrn binding
KR101468271B1 (ko) * 2009-03-19 2014-12-03 추가이 세이야쿠 가부시키가이샤 개량된 항체분자를 함유하는 의약 제제
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants
CA2759333A1 (en) 2009-04-22 2010-10-28 Merck Patent Gmbh Antibody fusion proteins with modified fcrn binding sites
US20120134984A1 (en) 2009-06-01 2012-05-31 Olga Lubman Molecules with extended half-lives and uses thereof
AU2010270979B2 (en) 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
AU2010303415B2 (en) 2009-10-07 2015-02-19 Macrogenics, Inc. Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
EP2507267B1 (en) 2009-12-02 2016-09-14 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life of fc fusion proteins
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
WO2011109400A2 (en) 2010-03-04 2011-09-09 Macrogenics,Inc. Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
TWI504609B (zh) 2010-11-23 2015-10-21 Glaxo Group Ltd 抗原結合蛋白質
BR112013013003A2 (pt) 2010-11-24 2016-08-09 Glaxo Group Ltd proteína de ligação de antígeno, e, composição farmacêutica
CA2824279A1 (en) 2010-12-22 2012-06-28 Cephalon Australia Pty Ltd Modified antibody with improved half-life
CN103476795B (zh) 2011-03-29 2016-07-06 罗切格利卡特公司 抗体Fc变体
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
KR102030531B1 (ko) 2011-05-21 2019-10-10 마크로제닉스, 인크. 탈면역화된 혈청-결합 도메인 및 혈청 반감기를 연장하기 위한 그것의 용도
US8883982B2 (en) 2011-06-08 2014-11-11 Acceleron Pharma, Inc. Compositions and methods for increasing serum half-life
WO2013014208A2 (en) 2011-07-27 2013-01-31 Glaxo Group Limited Antigen binding constructs
LT2771022T (lt) 2011-10-11 2020-12-10 Viela Bio, Inc. Cd40l-specifiniai iš tn3 kilę karkasai ir jų naudojimo būdai
CA3111357A1 (en) 2011-12-23 2013-06-27 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
SMT202100621T1 (it) 2012-07-13 2022-01-10 Roche Glycart Ag Anticorpi bispecifici anti-vegf/anti-ang-2 e loro impiego nel trattamento delle malattie vascolari oculari
BR112015002091A2 (pt) * 2012-08-02 2017-12-12 Hoffmann La Roche método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
US20140044675A1 (en) * 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
WO2014029752A1 (en) 2012-08-22 2014-02-27 Glaxo Group Limited Anti lrp6 antibodies
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
SMT202100464T1 (it) 2013-03-14 2021-11-12 Macrogenics Inc Molecole bispecifiche che sono immunoreattive con cellule effettrici immunitarie che esprimono un recettore di attivazione
AR095432A1 (es) 2013-03-15 2015-10-14 Glaxosmithkline Ip Dev Ltd Proteínas de unión a antígeno
UA116479C2 (uk) 2013-08-09 2018-03-26 Макродженікс, Інк. БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
US11384149B2 (en) 2013-08-09 2022-07-12 Macrogenics, Inc. Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
EP2840091A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific diabodies that are capable of binding gpA33 and CD3 and uses thereof
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
NZ760289A (en) 2014-02-06 2023-05-26 Hoffmann La Roche Interleukin-2 fusion proteins and uses thereof
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TWI701042B (zh) 2014-03-19 2020-08-11 美商再生元醫藥公司 用於腫瘤治療之方法及抗體組成物
US20170267780A1 (en) 2014-05-16 2017-09-21 Medimmune, Llc Molecules with altered neonate fc receptor binding having enhanced therapeutic and diagnostic properties
EP3157945A4 (en) 2014-06-20 2017-11-22 F. Hoffmann-La Roche AG Chagasin-based scaffold compositions, methods, and uses
JP6640834B2 (ja) 2014-08-11 2020-02-05 デリニア， インコーポレイテッド 自己免疫疾患の処置のために調節性ｔ細胞を選択的に活性化させる改変ｉｌ−２変異体
SG11201702544WA (en) 2014-09-29 2017-04-27 Univ Duke Bispecific molecules comprising an hiv-1 envelope targeting arm
PL3699198T3 (pl) 2014-11-17 2025-06-23 Regeneron Pharmaceuticals, Inc. Sposoby leczenia nowotworów z wykorzystaniem dwuswoistego przeciwciała cd3xcd20
TWI805046B (zh) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
WO2016161010A2 (en) 2015-03-30 2016-10-06 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
GB201506389D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
GB201506393D0 (en) * 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
EP3328427B1 (en) 2015-07-27 2024-05-29 The General Hospital Corporation Antibody derivatives with conditionally enabled effector function
CN108699145A (zh) 2015-09-02 2018-10-23 伊缪泰普有限公司 抗lag-3抗体
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
SG10202002577XA (en) 2015-09-21 2020-04-29 Aptevo Res & Development Llc Cd3 binding polypeptides
KR20210016479A (ko) 2015-12-04 2021-02-15 노파르티스 아게 항체 시토카인 그라프트된 조성물 및 면역조절을 위한 사용 방법
US20170204154A1 (en) 2016-01-20 2017-07-20 Delinia, Inc. Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases
PE20190353A1 (es) 2016-04-15 2019-03-07 Macrogenics Inc Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos
TWI784957B (zh) 2016-06-20 2022-12-01 英商克馬伯有限公司 免疫細胞介素
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
CN110198729A (zh) 2016-09-09 2019-09-03 豪夫迈·罗氏有限公司 卷曲蛋白的选择性肽抑制剂
JP7213180B2 (ja) * 2016-10-19 2023-01-26 エフ．ホフマン－ラ ロシュ アーゲー 免疫コンジュゲートを製造するための方法
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
MX2019005400A (es) 2016-11-08 2019-08-05 Delinia Inc Variantes de il-2 para el tratamiento de enfermedades autoinmunes.
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
JOP20190271A1 (ar) 2017-05-24 2019-11-21 Novartis Ag بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة
EA201992765A1 (ru) 2017-05-24 2020-03-25 Новартис Аг Белки на основе антител с привитым цитокином и способы их применения в лечении рака
BR112020007309A2 (pt) 2017-10-14 2020-09-29 Cytomx Therapeutics, Inc. anticorpos, anticorpos ativáveis, anticorpos biespecíficos e anticorpos ativáveis biespecíficos e métodos de uso dos mesmos
SG11202005732XA (en) 2017-12-19 2020-07-29 Xencor Inc Engineered il-2 fc fusion proteins
PT3844189T (pt) 2018-08-31 2025-01-29 Regeneron Pharma Estratégia de dosagem que mitiga a síndrome de libertação de citocinas para anticorpos bisepecíficos contra cd3/c20
CN112142847B (zh) * 2019-02-22 2023-05-05 武汉友芝友生物制药股份有限公司 改造的Fc片段，包含其的抗体及其应用
CA3146471A1 (en) 2019-08-06 2021-02-11 James K. Kranz Compositions comprising anti-bcma antigen binding proteins for treating bcma-mediated diseases or disorders
KR20220114595A (ko) * 2019-12-17 2022-08-17 암젠 인크 치료에서의 사용을 위한 이중 인터류킨-2/tnf 수용체 효현제
BR112023024804A2 (pt) 2021-05-28 2024-02-15 Glaxosmithkline Ip Dev Ltd Terapias de combinação para tratar câncer
JP2024530643A (ja) 2021-08-03 2024-08-23 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド バイオ医薬組成物および安定同位体標識ペプチドマッピング法
CA3233953A1 (en) 2021-10-05 2023-04-13 Matthew Bruce Combination therapies for treating cancer
CA3241017A1 (en) 2021-12-17 2023-06-22 Robert Ferris Combination therapies for hiv infections and uses thereof
CN119300858A (zh) 2022-04-29 2025-01-10 23和我公司 抗原结合蛋白
CN119790068A (zh) 2022-08-25 2025-04-08 葛兰素史克知识产权发展有限公司 抗原结合蛋白及其用途
AR130792A1 (es) 2022-10-20 2025-01-22 Glaxosmithkline Intellectual Property No 3 Ltd Proteínas de unión a antígeno
CN120112311A (zh) 2022-11-02 2025-06-06 Viiv保健英国第五有限公司 抗原结合蛋白
WO2025114862A1 (en) 2023-11-27 2025-06-05 Glaxosmithkline Intellectual Property Development Limited Il-33 binding antibodies
WO2025125137A1 (en) 2023-12-11 2025-06-19 Glaxosmithkline Intellectual Property Development Limited Baff specific antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
WO1997033617A1 (en) * 1996-03-13 1997-09-18 Protein Design Labs, Inc. Fas ligand fusion proteins and their uses

Also Published As

Publication number Publication date
NO20004218L (no) 2000-10-24
WO1999043713A1 (en) 1999-09-02
AU758240B2 (en) 2003-03-20
HK1036286A1 (en) 2001-12-28
BR9908226A (pt) 2000-10-24
EP1060194A1 (en) 2000-12-20
NO20004218D0 (no) 2000-08-23
PL199659B1 (pl) 2008-10-31
PL342497A1 (en) 2001-06-04
AU2784299A (en) 1999-09-15
CN1291995A (zh) 2001-04-18
CZ20003099A3 (cs) 2002-04-17
CN1204147C (zh) 2005-06-01
HUP0100813A2 (hu) 2001-06-28
JP2002505086A (ja) 2002-02-19
CA2320403A1 (en) 1999-09-02

Similar Documents

Publication Publication Date Title
HUP0100813A3 (en) Enhancing the circulating half-life of antibody-based fusion proteins
GB9718609D0 (en) Fusion protein
HUS1600018I1 (hu) Aril kondenzált azapoliciklusos vegyületek
EP1088888A4 (en) MERGED PROTEIN
AU5065198A (en) Fusion proteins having increased half-lives
ZA9810271B (en) Fused pyrazine compounds
AU3562299A (en) Inhibin-hbc fusion protein
GB9913437D0 (en) Fusion proteins
MA26681A1 (fr) Composes pyrazine
MA26587A1 (fr) Composes de triazine
DK0862197T3 (da) Sikringsstik
GB9828704D0 (en) Proteins
GB9816337D0 (en) Proteins
DE69812798D1 (de) Metallschmelzverfahren
SI1252192T1 (sl) Povecanje cirkulacijskega razpolovnega casa fuzijskih proteinov na osnovi protiteles
GB9716101D0 (en) Fused heterocyclic compounds
GB9811516D0 (en) Fusion proteins having increased half-lives
GB9803757D0 (en) Fusion proteins
GB9813653D0 (en) Fusion proteins
GB9713150D0 (en) Fusion proteins
GB9813018D0 (en) CD8-›2m fusion proteins
GB9816335D0 (en) Proteins
GB9816336D0 (en) Proteins
GB0315759D0 (en) Proteins
TW333341U (en) Improved eyeglasses